# Shanu Modi

Source: https://onco.cc/people/shanu-modi/  
OnCo record `shanu-modi` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led DESTINY-Breast01 and DESTINY-Breast04, the trials that created the HER2-low category and opened T-DXd to most breast cancers.

## Summary

Shanu Modi was lead investigator of DESTINY-Breast01, the study that won trastuzumab deruxtecan its first approval, and of DESTINY-Breast04, which showed the ADC halves the risk of progression in HER2-low disease previously treated as HER2-negative. That trial redefined breast cancer classification and extended ADC therapy to roughly half of all patients. She continues to lead ADC trials at MSKCC.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: breast; adc; her2-low
- Role: Breast Medical Oncologist, Memorial Sloan Kettering Cancer Center
- Specialisms: HER2-directed therapy; HER2-low breast cancer; Antibody-drug conjugates

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Modi%20S%5BAuthor%5D%20trastuzumab%20deruxtecan

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [HER2](https://onco.cc/targets/her2/)
- drugs: [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- institutions: [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)
- trials: [DESTINY-Breast04](https://onco.cc/trials/destiny-breast04/)
- key papers: [DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group](https://onco.cc/key-papers/paper-destiny-breast04-nejm-2022/)

---
JSON: https://onco.cc/api/v1/entities/shanu-modi.json